ADXN רווח נקי למניה ב-12 החודשים האחרונים Addex

The TTM net income per share distribution demonstrates yield dynamics, where -8.76 represents the current metric level. Addex Therapeutics (ADXN) develops small molecules for the therapy of neurological pathologies using allosteric modulation. The business focuses on combating dyskinesia in Parkinson's disease, although project success depends on patents and clinical trial outcomes amid fierce competition.

The development of allosteric modulators by Addex Therapeutics (ADXN) requires high R&D expenditures without current sales. This metric measures the final net income allocated per share annually. By analyzing the rolling annual earnings per share, an investor assesses the efficiency of the business's capitalization. Negative dynamics reflect a lack of operating leverage. Stagnation of this metric renders the current market valuation of the asset excessively risky.